The newest generation of antiobesity medications (AOMs)—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), dual action GLP-1/GIP combinations, triple action injectables, and emerging injectable and oral medications—have changed the landscape for weight management, bringing weight loss success to many for whom weight maintenance had previously not been possible.
Trending
- A Critical Look at Osteoporosis
- Cognitive Performance Nutrition
- RDs Shaping AI in the Field of Nutrition
- CPE Monthly: Vitamin D in Diabetes
- Editor’s Spot: Dietary vs Pharmacological Intervention
- Ask the Expert: Maltodextrin
- Focus on Fitness: Athlete Body Image and Disordered Eating
- Food for Thought: Healthy Holiday Travels